Is Qelbree (viloxazine extended‑release) a stimulant medication?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Is Qelbree a Stimulant?

No, Qelbree (viloxazine extended-release) is definitively not a stimulant—it is classified as a non-stimulant medication for ADHD. 1

Medication Classification

  • Qelbree is a serotonin-norepinephrine modulating agent (SNMA), not a psychostimulant like methylphenidate or amphetamines. 1

  • The FDA has approved viloxazine ER as a non-stimulant treatment option for ADHD in children (6-17 years) and adults. 2, 3, 4

  • Guidelines explicitly categorize available ADHD medications into two groups: stimulants (methylphenidate and amphetamines) versus non-stimulants (atomoxetine, guanfacine, clonidine), with viloxazine falling into the non-stimulant category. 1

Mechanism of Action

Viloxazine's pharmacology clearly distinguishes it from stimulants:

  • Viloxazine moderately inhibits norepinephrine transporter (NET) and modulates serotonergic activity as a selective 5-HT2B receptor antagonist and 5-HT2C receptor agonist. 1, 5

  • In contrast, stimulants work primarily through dopamine and norepinephrine transporter inhibition, with methylphenidate also affecting vesicular monoamine transporter 2 and amphetamines inhibiting monoamine oxidase activity. 1

  • The serotonin modulating activity is considered "an important (if not the predominant) component of its mechanism of action," which fundamentally differs from stimulant pharmacology. 1

Clinical Context

  • Viloxazine was originally developed as an antidepressant in the 1970s and has been repurposed for ADHD treatment, reflecting its distinct pharmacological profile from traditional stimulants. 1

  • The medication can be used as monotherapy or in combination with psychostimulants when stimulant therapy alone provides inadequate response, further demonstrating its non-stimulant classification. 6

  • Common side effects differ from stimulants: while both can cause decreased appetite, viloxazine notably causes somnolence and fatigue in children (not typical stimulant effects), whereas adults experience insomnia more commonly. 7, 2

Important Clinical Distinction

A critical pitfall is assuming all ADHD medications are stimulants. Viloxazine represents a novel non-stimulant option with a unique mechanism that may benefit patients who cannot tolerate or do not respond adequately to traditional stimulants. 4, 5

References

Related Questions

What is the maximum recommended dose of Qelbree (viloxazine extended‑release) for patients 12 years and older and for children 6–11 years old?
When should Qelbree (viloxazine extended‑release) be taken each day?
How should I discontinue Qelbree (viloxazine) 400 mg?
Is it common for patients to be treated with both Qelbree (viloxazine) and a stimulant for attention‑deficit/hyperactivity disorder?
How does Qelbree (viloxazine) work as a long‑acting medication, and can it be taken as a liquid?
What are the anesthesia considerations for a patient with empty sella syndrome?
Is disc desiccation the primary cause of degenerative disc disease (DDD), or does DDD precede disc desiccation?
At age 21, I have been told that intervertebral disc desiccation is a normal part of aging; is this abnormal at my age, and what is the long‑term prognosis for spinal mobility into my 50s and 60s?
When is a pylorus-preserving pancreaticoduodenectomy (PPPD) preferred over a standard (non‑pylorus‑preserving) Whipple procedure?
What causes frequent eye irritation at night and how should it be treated?
Can Qulipta (atogepant) cause hypertension?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.